This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
by Zacks Equity Research
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
by Zacks Equity Research
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
by Zacks Equity Research
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
Best Momentum Stock to Buy for May 7th
by Zacks Equity Research
LDOS, FCBC and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 7, 2024.
Best Value Stocks to Buy for May 7th
by Zacks Equity Research
UTHR and NWPX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 7, 2024.
United Therapeutics (UTHR) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
United Therapeutics (UTHR) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
What Makes United Therapeutics (UTHR) a New Buy Stock
by Zacks Equity Research
United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.